agneau-chaste

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• acne [Insufficient Evidence]
• aging skin [Insufficient Evidence]
• amenorrhea [Insufficient Evidence]
• anxiety [Insufficient Evidence]
• BPH [Insufficient Evidence]
• dementia [Insufficient Evidence]
• dysmenorrhea [Insufficient Evidence]
• female infertility [Insufficient Evidence]
• fibrocystic breast dz [Insufficient Evidence]
• fracture [Possibly Ineffective]
• hyperprolactinemia [Insufficient Evidence]
• insect repellent [Insufficient Evidence]
• insomnia [Insufficient Evidence]
• lactation stimulation [Insufficient Evidence]
• mastalgia [Possibly Effective]
• menopausal sx [Insufficient Evidence]
• menorrhagia [Insufficient Evidence]
• migraine [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• premenstrual dysphoric disorder [Insufficient Evidence]
• premenstrual syndrome [Possibly Effective]
• rheumatoid arthritis [Insufficient Evidence]
• sexual dysfxn [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

aging skin

[Insufficient Evidence]

Dose: 400 mg PO qd

insect repellent

[Insufficient Evidence]

Dose: apply extract topically

mastalgia

[Possibly Effective]

Dose: 3.2-40 mg extract PO qd

menopausal sx

[Insufficient Evidence]

Dose: 15 mg extract PO bid; Alt: 1000 mg dried fruit PO qd; 400 mg PO qd

premenstrual dysphoric disorder

[Insufficient Evidence]

Dose: 20-40 mg extract PO qd

premenstrual syndrome

[Possibly Effective]

Dose: 4-40 mg extract PO qd; Alt: 3.2-6 mg extract PO bid; 3.5-4.2 mg PO qd on days 16-35 of menstrual cycle; 40 gtt extract PO qd

sexual dysfxn

[Insufficient Evidence]

Dose: 3.2-4.8 mg extract PO qd; Alt: 40 gtt extract PO qd